Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin

doi:10.5306/wjco.v3.i10.137

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 10

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2889)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series.

Item

Count

PDF

548

HTML

2190

Figures (1-2)

151

Sum=2889

Oct 10, 2012 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Clin Oncol. Oct 10, 2012; 3(10): 137-141
Published online Oct 10, 2012. doi: 10.5306/wjco.v3.i10.137

Full Size Figure Download Figure

Figure 2 Kaplan-Meier survival curve for all patients over the period of follow-up. A: Kaplan-Meier progression-free survival curve. Median progression free survival (PFS) was 10.6 mo (95% CI: 5.91-15.3); B: Kaplan-Meier overall survival (OS) curve. Median overall survival was 20.93 mo (95% CI: 16.07-25.8).

Citation: Grenader T, Rosengarten O, Isacson R, Plotkin Y, Gabizon A. Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin. World J Clin Oncol 2012; 3(10): 137-141
URL: https://www.wjgnet.com/2218-4333/full/v3/i10/137.htm
DOI: https://dx.doi.org/10.5306/wjco.v3.i10.137